
|Articles|March 25, 2020
Q2 Solutions Collaborates with University of Texas Medical Branch to Accelerate COVID-19 Vaccines
Advertisement
Q2 Solutions, a clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, announced its collaboration with the University of Texas Medical Branch to develop a novel assay for COVID-19 tests. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Breaking the Efficacy Ceiling in IBD and Beyond
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
5




